NCT03859388
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 18 words
- Trial completed
- Primary completion date changed from estimate of Dec 31, 2025 to Feb 28, 2022
- Publications: details revised at 6 of 6 entries
- Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v7
- Notable Primary and study completion dates: Dec 31, 2022 to Dec 31, 2024v6
- Notable Primary and study completion dates: Jun 2022 to Dec 31, 2022v5
- Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
- Primary and study completion dates: Dec 2021 to Jun 2022
Show 2 earlier versionsHide 2 earlier versions
- Notable Primary and study completion dates: Dec 2020 to Dec 2021
- Eligibility criteria revised
- Minor Start date changed from estimate of Mar 2019 to Mar 1, 2019v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in the percentage of donor-derived cell-free DNA
Timeframe: 12 months
Secondary (8)
Difference in Change in Donor-Derived Cell-Free DNA Between Responders and Non-Responders
Change in estimated glomerular filtration rate (GFR)
Change in glomerulitis histology score with treatment
Change in peritubular capillaritis histology score with treatment
Change in C4d score with treatment
Show 3 moreShow less
Change in glomerular double contours score with treatment
Change in interstitial fibrosis score with treatment
Change in tubular atrophy score with treatment
Arms and interventions
Chronic ABMR
Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
Sites
1 site in 1 country
- Cedars-Sinai Medical CenterLos Angeles, California, United States